NDA 211225 · Novartis
Zykadia
Ceritinib · Oral · Kinase Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Oct 7, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 18, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
49
3 Phase 3, 6 recruiting
FAERS reports
2,384
1,941 serious, 553 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1)] . ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )
Mechanism: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZYKADIA · CERITINIB 150MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceritinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- Molecular Profiling of Advanced Soft-tissue SarcomasPivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT03784014 · 603 participants · Start Oct 19, 2019 · Primary completion Dec 1, 2023
Drug: Nilotinib; Ceritinib and 6 more · For: Soft Tissue Sarcoma
Sites: Bordeaux, France; Dijon, France; Lille, France · 17 sites in all
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyPivotal-lookingRecruiting
Giselle ShollerAcademic, hospital or other
NCT02559778 · 500 participants (planned) · Start Sep 2015 · Primary completion Sep 2030
Drug: Ceritinib; dasatinib and 3 more · For: Neuroblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Oakland, California · 28 sites in all
- LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01828099 · 376 participants · Start Jul 9, 2013 · Primary completion Jun 24, 2016
Drug: Ceritinib; Pemetrexed and 2 more · For: Non-Small Cell Lung Cancer
Sites: CABA, Argentina; La Rioja, Argentina; Woolloongabba, Australia · 167 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02299505 · 306 participants · Start Apr 9, 2015 · Primary completion Jun 16, 2016
Drug: ceritinib · For: Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Loma Linda, California; Indianapolis, Indiana · 73 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01283516 · 304 participants · Start Jan 24, 2011 · Primary completion May 3, 2016
Drug: LDK378 · For: Tumors Characterized by Genetic Abnormalities of ALK
Sites: Aurora, Colorado; Boston, Massachusetts; New York, New York · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression430
- diarrhoea427
- nausea343
- death281
- vomiting224
- metastases to central nervous system172
- fatigue134
- non-small cell lung cancer130
- decreased appetite119
- disease progression112
- dyspnoea102
- abdominal pain100
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 98 |
| 2015 | 332 |
| 2016 | 371 |
| 2017 | 311 |
| 2018 | 312 |
| 2019 | 182 |
| 2020 | 182 |
| 2021 | 221 |
| 2022 | 183 |
| 2023 | 91 |
| 2024 | 53 |
| 2025 | 29 |
| 2026 | 17 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zykadia (Ceritinib)
2024 spending
$4.6M
Beneficiaries
61
424 claims
Per beneficiary
$74,619
$147.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,105,689 |
| 2021 | $4,142,424 |
| 2022 | $3,999,309 |
| 2023 | $4,498,924 |
| 2024 | $4,551,745 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC, Tan DSW, Chiari R, et al. · Lancet 2017 · Clinical Trial, Phase III, Comparative Study
- Ceritinib Bests Chemo for Untreated ALK+ NSCLC.
· Cancer Discov 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
Khozin S, Blumenthal GM, Zhang L, et al. · Clin Cancer Res 2015 · Clinical Trial, Multicenter Study
- The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
Amanam I, Gupta R, Mambetsariev I, et al. · Future Oncol 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of severe renal impairment on the pharmacokinetics of brigatinib.
Gupta N, Hanley MJ, Kerstein D, et al. · Invest New Drugs 2021 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
Zhu Q, Hu H, Weng DS, et al. · BMC Cancer 2017 · Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.